SAN DIEGO, Oct. 30 /PRNewswire/ -- Nventa Biopharmaceuticals Corporation announced today that Gregory M. McKee, the Company's President and Chief Executive Officer, is scheduled to make a presentation on Thursday, November 1, 2007 at 10:30 am Pacific Time at the BIOCOM Investor Conference 2007, which is taking place at the San Diego Marriott Del Mar Hotel.
Gregory McKee will provide an overview of the Company and will discuss the Company's progress with its investigational therapeutic vaccine, HspE7 for human papillomavirus (HPV)-related diseases, and also the Company's business strategy. An audio webcast of Nventa's presentation, with an accompanying slide presentation, will be available on http://events.powerstream.net/002/00436/20071101_SDIC/ or on the Company's website at http://www.nventacorp.com on the day of the event. Participants will need to allow adequate time to download any software necessary for the webcast.
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN.
For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at http://www.nventacorp.com.
CONTACT: Donna Slade, Director, Investor Relations of Nventa
Biopharmaceuticals Corporation, +1-858-202-4945, fax, +1-858-450-6849,
dslade@nventacorp.com
Web site: http://www.nventacorp.com/
